Literature DB >> 20870296

Free light chain monomers in the diagnosis of multiple sclerosis.

Batia Kaplan1, Boris M Aizenbud, Sizilia Golderman, Regina Yaskariev, Ben-Ami Sela.   

Abstract

A new procedure of free light chain (FLC) analysis was developed to assist the diagnosis of multiple sclerosis (MS). In this procedure, Western blotting technique was used to analyze monomeric and dimeric FLCs in the cerebrospinal fluid (CSF) and serum of patients with MS and other neurological diseases. The intensity of immunoreactive FLC bands was quantified by a specially developed software. Analysis of the obtained monomer/dimer patterns of κ and λ type FLCs allowed the determination of the diagnostically useful FLC parameters. The combined use of three FLC indices accounting for monomeric FLC-κ level and κ/λ ratio values in the CSF and serum was found to be of promising diagnostic importance for differentiation of MS from other non-MS neurological diseases.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20870296     DOI: 10.1016/j.jneuroim.2010.09.002

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  22 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

2.  Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysis.

Authors:  Olga Kukuy; Batia Kaplan; Sizilia Golderman; Alexander Volkov; Adrian Duek; Merav Leiba; Ilan Ben-Zvi; Avi Livneh
Journal:  Clin Exp Nephrol       Date:  2019-02-08       Impact factor: 2.801

3.  The FLC dimer with lambda type may false-migrate to the position of "albumin" band by urine protein electrophoresis on Sebia agarose gel-based detection system.

Authors:  Changqiang Chen; Peizhan Chen; Xuqian Fang
Journal:  J Clin Lab Anal       Date:  2018-08-27       Impact factor: 2.352

4.  Experimental laboratory biomarkers in multiple sclerosis.

Authors:  Borros Arneth; Jörg Kraus
Journal:  Wien Med Wochenschr       Date:  2022-03-07

5.  Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis.

Authors:  B Kaplan; S Golderman; E Ganelin-Cohen; A Miniovitch; E Korf; I Ben-Zvi; A Livneh; S Flechter
Journal:  Clin Exp Immunol       Date:  2017-12-26       Impact factor: 4.330

6.  Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?

Authors:  Judith A Brebner; Robert A Stockley
Journal:  F1000 Med Rep       Date:  2013-02-01

7.  Detection of oligoclonal IgG kappa and IgG lambda bands in cerebrospinal fluid and serum with Hevylite™ antibodies. comparison with the free light chain oligoclonal pattern.

Authors:  David Zeman; Pavel Hradílek; Zdeněk Svagera; Eva Mojžíšková; Ivana Woznicová; Olga Zapletalová
Journal:  Fluids Barriers CNS       Date:  2012-02-23

8.  Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.

Authors:  Stefan Presslauer; Dejan Milosavljevic; Wolfgang Huebl; Silvia Parigger; Gabriele Schneider-Koch; Thomas Bruecke
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

9.  Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies.

Authors:  Anette H Draborg; Magnus C Lydolph; Marie Westergaard; Severin Olesen Larsen; Christoffer T Nielsen; Karen Duus; Søren Jacobsen; Gunnar Houen
Journal:  PLoS One       Date:  2015-09-24       Impact factor: 3.240

10.  Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis.

Authors:  Makbule Senel; Hayrettin Tumani; Florian Lauda; Stefan Presslauer; Rehaneh Mojib-Yezdani; Markus Otto; Johannes Brettschneider
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.